The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome

Atypical hemolytic-uremic syndrome (aHUS) is a chronic systemic disease of a genetic nature, which is based on uncontrolled activation of the alternative complement pathway, leading to generalized thrombosis in the vessels of the microvasculature (complement-mediated thrombotic microangiopathy). To...

Full description

Bibliographic Details

Published in:	Терапевтический архив
Main Authors:	Yulia V. Lavrishcheva, Alexander A. Yakovenko, Dmitrii A. Kudlai
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2020-07-01
Subjects:	atypical hemolytic-uremic syndrome complement-mediated thrombotic microangiopathy acute kidney injury pathogenetic therapy eculizumab biosimular
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/35000/pdf